secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001171843-22-005503
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agenus Q2 net loss narrows to $49M; botensilimab shows 24% ORR in MSS CRC
-------------------------------------------------------------------------

- Net loss of $49.2M ($0.17/share) vs $84.0M ($0.37) in Q2 2021; revenue $20.9M (up from $10.7M).
- Cash & investments $238M at June 30, 2022, down from $307M at Dec 31, 2021.
- Botensilimab/balstilimab combo achieved 24% ORR and 73% DCR in 41 heavily pretreated MSS CRC patients.
- Phase 2 randomized trials in MSS CRC, melanoma, and pancreatic cancer to start later this year.
- First patient dosed in Phase 1 study of AGEN1571 (anti-ILT2) in advanced solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000117184322005503/0001171843-22-005503-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000117184322005503/f8k_080922.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-005503

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer